semaglutide symptoms day 1 What Should I Expect the First Week of GLP-1 Safety & Side Effects |

What's New: TRIUMPH-1 Announced (May 21, 2026) Results announced: May 21, 2026 Eli Lilly press release Trial status: Complete all primary and key secondary endpoints met Key result: 28.3% average weight loss at 80 weeks (12mg dose, N=2,339) NDA impact: Eli Lilly now has the primary efficacy dataset required for Q4 2026 NDA filing Next trial to watch: TRIUMPH-2 (diabetes) expected Q3Q4 2026 Introduction On May 21, 2026, Eli Lilly announced the topline results of TRIUMPH-1 the pivotal Phase 3 trial that determines whether retatrutide will receive FDA approval for obesity treatment

GHK-Cu is a copper II-coordinated tripeptide composed of glycine, histidine, and lysine

A scabby rash developed around her belly button, which was oozing pus

Whether you need intensive treatment or a step-down plan, Nova focuses on evidence-based care that supports long-term stability, safer choices, and a clearer path forward